Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
BMC pharmacology & toxicology · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
PharmacovigilanceHumansFemaleSemaglutideAdverse Drug Reaction Reporting SystemsDatabases, FactualMaleProduct Surveillance, PostmarketingTirzepatideMental DisordersWorld Health OrganizationGlucagon-Like Peptide 1AdultMiddle AgedHypoglycemic AgentsLiraglutideGlucagon-Like PeptidesDisproportionality analysisGLP-1RAsNeuropsychiatryVigiBaseDisproportionality AnalysisVigibaseGlp-1ras
Come citare questo studio
Liang J, Bo L, Miao X, Guo X, Xu J, He J, Ye X. (2026). Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).. BMC pharmacology & toxicology. DOI: 10.1186/s40360-026-01190-4
Consulta la pubblicazione originale ↗